` EPRX (Eupraxia Pharmaceuticals Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

EPRX
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, EPRX has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +91% compared to the S&P TSX Composite Index (Canada)'s +21% growth.

Stocks Performance
EPRX vs S&P TSX Composite Index (Canada)

Loading
EPRX
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
EPRX vs S&P TSX Composite Index (Canada)

Loading
EPRX
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
EPRX vs S&P TSX Composite Index (Canada)

Loading
EPRX
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Eupraxia Pharmaceuticals Inc vs Peers

S&P TSX Composite Index (Canada)
EPRX
ABBV
CYTH
AMGN
GILD
Add Stock

Eupraxia Pharmaceuticals Inc
Glance View

Market Cap
246.3m CAD
Industry
Biotechnology

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.

EPRX Intrinsic Value
Not Available
Back to Top